Peetz Christopher sold $1.6M of MIRM
Peetz Christopher (CHIEF EXECUTIVE OFFICER) sold 16,595 shares of Mirum Pharmaceuticals, Inc. (MIRM) at $95.34 ($1.58M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The CEO’s open-market sale at ~$95.34/share is disclosed with a pre-arranged 10b5-1 plan, which typically reduces the immediacy of any negative signal.
Market read
Provides a concrete insider selling datapoint (size, price, post-sale holdings) but no new fundamental catalyst.
What to watch
Traders may over-interpret single insider sales; the key is whether there is a pattern of repeated selling or concurrent positive/negative corporate catalysts (not provided here).
Background
The article is an SEC Form 4 insider transaction disclosure for Mirum Pharmaceuticals (MIRM).
Ticker impact
Mirum Pharmaceuticals CEO Peetz Christopher sold 16,595 shares in an open-market transaction disclosed on SEC Form 4.
Low likelihood of a sustained price move solely from this Form 4; any reaction is likely transient.
The filing provides a specific sale size and price, but the transaction is explicitly under a pre-arranged 10b5-1 plan, reducing interpretive weight versus discretionary selling.
Market effects
Minimal; this is company-specific insider activity with no stated operational/regulatory catalyst.
None indicated.
None indicated.
Counterpoint
Because the sale is on a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than negative fundamentals.
Key entities
- issuerMirum Pharmaceuticals, Inc.
Subject of the insider transaction disclosure (Form 4).
- insiderPeetz Christopher
CEO and director who sold shares under a 10b5-1 plan.
